Kostantinos Galanis

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

M. Buti, R. Idilman, C. Yurdaydın, 2015, Journal of hepatology.

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

M. Buti, T. Berg, R. Idilman, 2018, Journal of hepatology.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

M. Buti, T. Berg, R. Idilman, 2017, Hepatology.

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.

M. Buti, R. Idilman, C. Yurdaydın, 2016, Journal of hepatology.

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

M. Buti, R. Idilman, C. Yurdaydın, 2015, Journal of hepatology.